Imugene share price surges 18% to lead the ASX 200 on Thursday

What's behind the meteoric gain for this ASX 200 healthcare stock today?

| More on:
A man flies into the sky over a city building-scape with a rocket jet pack sketched onto his back representing the Imugene share price skyrocketing today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Imugene was the best performer on the ASX 200 today. Its share price gained 20% and closed the session at 20 cents 
  • Imugene helped the ASX 200 healthcare sector outperform today – it was the only sector in the green at the closing bell 
  • Yesterday, Imugene released exciting news relating to the phase 1 clinical trial of its cancer-killing oncolytic virus 

The Imugene Limited (ASX: IMU) share price took off today despite the company's silence.

However, today's gains might have been a belated reaction to the news the company announced to the ASX yesterday.

As of Thursday's close, the Imugene share price is 20 cents. That's 17.65% higher than it was at the end of Wednesday's session. It reached an intraday high of 21.5 cents today, representing a 26.47% gain.

For context, the S&P/ASX 200 Index (ASX: XJO) finished the day 1.6% lower.

Let's take a closer look at the latest news from the clinical-stage immuno-oncology company.

Did this drive the Imugene share price today?

The Imugene share price leapt higher today as the healthcare sector outperformed.

In fact, the stock's sector, represented by the S&P/ASX 200 Health Care Index (ASX: XHJ), was the only one in the green today. It closed 0.1% higher and was, perhaps unsurprisingly, led by Imugene.

The stock's movement comes one day after the company announced the first patient has been dosed in its phase 1 clinical trial of its cancer-killing oncolytic virus CF33-hNIS, Vaxinia.

The trial is the first time the virus has come up against tumours in humans.

It has previously been shown to shrink colon, lung, breast, ovarian, and pancreatic cancer tumours in preclinical laboratory and animal models.

The study is being run in partnership with City of Hope. That's the cancer treatment and research organisation that developed the virus. The study aims to recruit 100 patients across Australia and the United States.

The Imugene share price gained 3% yesterday. Though, the stock has notably underperformed throughout 2022 so far.

It is 53% lower than it was at the start of 2022. It has also fallen 50% since this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »